Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1182 participants.

Also called NCT06183931

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,182 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06183931
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, Denmark, France, Germany, Greece, Ireland, Israel, Italy, Japan, Netherlands, Norway, Poland, South Korea, Spain, Sweden, Switzerland, Taiwan, Türkiye, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06183931. Randomized; quadruple masking; primary purpose treatment. Start 2024-01-11 (actual); primary completion 2027-12-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
Acronym
DepleTTR-CM
Condition
Transthyretin Amyloid Cardiomyopathy
Intervention (Drug)
ALXN2220
Intervention (Drug)
Placebo
Lead sponsor
Alexion Pharmaceuticals, Inc. (class: industry)

Record details

Record id
cardio:ct-nct06183931
Content hash
a9fcde2d9e1c1545dccfba2578b763c9cd31f8c5bce66f4b861ba874664f0556